Helix BioPharma Corp. Strengthens Executive Leadership to Support U.S. Listing Strategy and Next Phase of Clinical Development

Executive Summary

• Helix BioPharma Corp. announced the appointments of Helen Middleton as General Counsel and David Browning as Vice President of Clinical Operations.
• The appointments are part of the company's strategy to strengthen executive leadership and operational infrastructure in preparation for a planned U.S. securities exchange listing and the advancement of its lead candidate, L-DOS47, into Phase IB/Randomized Phase II studies.

Key Details

• Appointments:
  • Helen Middleton appointed as General Counsel. She brings over 30 years of experience in pharmacy, law, and life sciences, having served in senior legal roles at Sidley Austin LLP, Matheson LLP, Mundipharma International, Ipsen, and Abcam. She will oversee legal affairs, governance, compliance, and strategic transactions.
  • David Browning appointed as Vice President of Clinical Operations. He brings over 30 years of experience leading global clinical development programs, having overseen more than 30 Phase I-III clinical studies. He will lead operational planning and execution for clinical development programs, including LDOS007.
• Strategic Context: The leadership changes support the company's "capital markets roadmap," including the preparation of a base shelf prospectus and the completion of auditor reviews for second-quarter financials.
• Pipeline Updates: The release notes the advancement of L-DOS47 through LDOS007, the planned Phase IB/Randomized Phase II study in first-line non-small cell lung cancer (NSCLC).

Notable Quotes

• Thomas Mehrling, MD, PhD, CEO: “The next stage of Helix’s evolution demands a different kind of company than the one we were building two years ago... Helen and David are exceptional additions to Helix. Helen brings decades of experience navigating the legal and governance challenges faced by growing life sciences companies, while David has successfully led complex global oncology programs from planning through execution.”
• Helen Middleton, General Counsel: “Helix has reached an important point in its evolution, and I look forward to helping build the legal and governance framework that supports the Company’s clinical and corporate ambitions.”
• David Browning, VP of Clinical Operations: “The Company has built an encouraging clinical foundation for L-DOS47, and I look forward to helping execute its next stage of development with the operational excellence required to bring this program forward, and, ultimately, to patients.”